- Home
- MYGN vs VCV Comparison
MYGN vs VCV Comparison
Compare MYGN & VCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- VCV
- Stock Information
- Founded
- MYGN 1991
- VCV 1993
- Country
- MYGN United States
- VCV United States
- Employees
- MYGN N/A
- VCV N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VCV Trusts Except Educational Religious and Charitable
- Sector
- MYGN Health Care
- VCV Finance
- Exchange
- MYGN Nasdaq
- VCV Nasdaq
- Market Cap
- MYGN 423.1M
- VCV 491.4M
- IPO Year
- MYGN 1995
- VCV N/A
- Fundamental
- Price
- MYGN $3.91
- VCV $10.22
- Analyst Decision
- MYGN Hold
- VCV
- Analyst Count
- MYGN 15
- VCV 0
- Target Price
- MYGN $15.14
- VCV N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- VCV 107.9K
- Earning Date
- MYGN 08-12-2025
- VCV 01-01-0001
- Dividend Yield
- MYGN N/A
- VCV 4.09%
- EPS Growth
- MYGN N/A
- VCV N/A
- EPS
- MYGN N/A
- VCV 0.13
- Revenue
- MYGN $831,300,000.00
- VCV N/A
- Revenue This Year
- MYGN N/A
- VCV N/A
- Revenue Next Year
- MYGN $6.64
- VCV N/A
- P/E Ratio
- MYGN N/A
- VCV $75.82
- Revenue Growth
- MYGN 7.38
- VCV N/A
- 52 Week Low
- MYGN $3.78
- VCV $8.05
- 52 Week High
- MYGN $29.30
- VCV $10.40
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- VCV 50.64
- Support Level
- MYGN $4.43
- VCV $9.96
- Resistance Level
- MYGN $4.83
- VCV $10.08
- Average True Range (ATR)
- MYGN 0.25
- VCV 0.14
- MACD
- MYGN -0.10
- VCV -0.01
- Stochastic Oscillator
- MYGN 9.32
- VCV 32.50
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About VCV Invesco California Value Municipal Income Trust
Invesco California Value Municipal Income Trust is engaged in the field of financial services. Its objective is to seek to provide common shareholders with a high level of current income exempt from federal and California income taxes, consistent with preservation of capital.